Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | PARP1 | P09874 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.35 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673205 | 0.75 | PARP1 (1.00) | ALDH1A1RXFP1PARP1POLBDAO | |
| SCHEMBL1133601 | 0.75 | PARP1 (1.00) | ALDH1A1RXFP1PARP1POLBDAO | |
| SCHEMBL15533169 | 0.72 | PARP1 (0.49) | PARP1CYP1A2 | |
| SCHEMBL6429242 | 0.72 | ALDH1A1 (0.49) | ALDH1A1PARP1POLBTP53HPGD | |
| SCHEMBL9044986 | 0.69 | POLB (0.44) | ALDH1A1RXFP1PARP1POLBDAO | |
| SCHEMBL16796840 | 0.69 | ALDH1A1 (0.46) | ALDH1A1RXFP1PARP1POLBDAO | |
| SCHEMBL25403036 | 0.68 | PDE5A (0.56) | ALDH1A1RXFP1PARP1POLBDAO | |
| SCHEMBL3212919 | 0.65 | ALDH1A1 (0.46) | ALDH1A1RXFP1PARP1POLBDAO | |
| SCHEMBL30273087 | 0.64 | PARP1 (0.53) | ALDH1A1RXFP1PARP1POLBDAO | |
| SCHEMBL2274845 | 0.63 | ADORA3 (0.37) | ALDH1A1RXFP1PARP1POLBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104098756-B | Thermoset composition, cured film and the electronic component with this cured film | 捷恩智株式会社 | 2018-10-19 | — | — | CN | claimed |
| CN-102924460-A | 4H-pyrrolo[1, 2-a] benzimidazole derivative and synthesizing method and application thereof | UNIV NANJING NORMAL | 2013-02-13 | — | — | CN | claimed |
| CN-1286615-A | keratinous fibre oxidation dyeing composition contg. laccase and dyeing method using same | OREAL (FR) | 2001-03-07 | — | — | CN | claimed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| EP-4493221-A2 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2024182772-A2 | MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-116370466-B | Imidazole ligand complex compound pharmaceutical composition and application thereof | 海南医学院 | 2023-10-10 | — | — | CN | disclosed |
| US-20230312613-A1 | HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312613-A1 | HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-10-05 | — | — | US | disclosed |
| US-20040006054-A1 | Cytotoxic N-unsubstituted indoles and cyclopent(b)indoles and method of making and using same | NATIONAL INSTITUTES OF HEALTH | 2004-01-08 | — | — | US | disclosed |
| US-6657052-B1 | Labeling DNA or RNA at a specific site consisting of stable precursor, and only becomes reactive upon activation; alkylating only phosphodiester groups; lactonization reaction traps the trialkylphosphate in a stable form. | UNIVERSITY OF ARKANSAS | 2003-12-02 | — | — | US | disclosed |
| US-20030139609-A1 | Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-24 | — | — | US | disclosed |
| US-20030119022-A1 | Recognition and cleavage at the DNA major groove | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-26 | — | — | US | disclosed |
| WO-2000043005-A1 | TREATMENT OF NEOPLASMS WITH THE YUJUNGAMYCINS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2000-07-27 | — | — | WO | disclosed |
| US-5521200-A | ANTICONVULSANTS AND TREATMENT OF ANXIETY | HO WINSTON (US) | 1996-05-28 | — | — | US | disclosed |
| US-5246955-A | Pyrrolo(1,2-a)benzimidazole 5,8-diones, antitumor | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5015742-A | Antitumor agents | ARIZONA BOARD OF REGENTS (US) | 1991-05-14 | — | — | US | disclosed |
| US-4242513-A | CHROMOGENS; PRESSURE AND HEAT SENSITIVE MARKING | APPLETON PAPERS INC. (US) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006054-A1 | Cytotoxic N-unsubstituted indoles and cyclopent(b)indoles and method of making and using same | TDO2, MDH2, CYP11B1 | ALDH1A1 397/4885RXFP1 4430/4885PARP1 892/4885 |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | ALDH1A1 2930/4885RXFP1 2599/4885PARP1 562/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | ALDH1A1 2349/4885RXFP1 604/4885PARP1 3704/4885 |
| US-20030139609-A1 | Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles | DUT, CYC1, DHRS9 | ALDH1A1 1476/4885RXFP1 4563/4885PARP1 812/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | ALDH1A1 4449/4885RXFP1 287/4885PARP1 3491/4885 |
| US-20230312613-A1 | HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | DDT, VDAC2, KCNC1 | ALDH1A1 649/4885RXFP1 4842/4885PARP1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.